Avadel Pharmaceuticals PLC (AVDL) reported a net earnings per share (EPS) of $0.00 for the third quarter of fiscal 2025, falling short of the Wall Street consensus estimate of $0.07. Revenue remained flat at $0.1 billion, matching expectations but not indicating growth.
The results highlight operational challenges for the company, which focuses on developing and commercializing pharmaceutical products, including LUMRYZ, an extended-release formulation of sodium oxybate for treating narcolepsy. Avadel employs 188 full-time staff and utilizes advanced drug delivery technologies such as MICROPUMP and LIQUITIME to address patient needs.
The company will host an earnings conference call to discuss these results further and provide additional insights into its business performance. Upcoming earnings are scheduled for May 4, 2026, with an EPS estimate of $0.1105 and revenue expectations of $0.1 billion.
Investors should consider reviewing the complete earnings release and management's commentary for a comprehensive understanding of the quarter's performance and future outlook.